Vanguard Group
DRUG

Vanguard Group’s Bright Minds Biosciences DRUG Stock Holding History

Vanguard Group’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.79M Buy
48,576
+3,473
+8% +$232K ﹤0.01% 3358
2025
Q3 		$2.74M Buy
45,103
+13,120
+41% +$509K ﹤0.01% 3476
2025
Q2 		$835K Buy
+31,983
New +$959K ﹤0.01% 3786

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group's DRUG Position: Q4 2025 in Review

Vanguard Group increased its Bright Minds Biosciences (DRUG) stake by 7.7% in Q4 2025, buying an estimated $232K and bringing the position to 48,576 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

Vanguard Group first reported a position in DRUG in Q2 2025 and has held it in 3 quarters since. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • Vanguard Group held 48,576 shares of Bright Minds Biosciences worth $3.79M as of Q4 2025.
  • Vanguard Group bought 3,473 Bright Minds Biosciences shares in Q4 2025, an estimated $232K.
  • Bright Minds Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3358 holding.
  • Vanguard Group first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 3 quarters since.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.